SkyePharma says that its development and marketing partner Mundipharma has successfully completed a paediatric study with positive results on its flagship asthma combination drug Flutiform.

Mundipharma has conducted a study for the treatment of asthma in 211 children aged four to 12 and compared Flutiform at its lowest dose (100 mcg fluticasone and 10mcg formoterol) to GlaxoSmithKline’s Seretide (100 mcg fluticasone & 50 mcg salmeterol). The trial has demonstrated comparable efficacy between the treatment arms, in terms of an improvement in lung function.

SkyePharma’s chief executive Frank Condella said the paediatric trial “is a further important step in the development of the product” and follows the successful completion of the long-term safety study in 2007. He added that the release of this data “is the first of a number of important announcements that we shall be making regarding Flutiform over the coming months”.

The company is now waiting for the results to come through from various late-stage Flutiform trials. Mr Condella said that “we look forward to announcing the first of three pivotal clinical efficacy trial results in the coming weeks and to progressing the path of this important pipeline product through to market”.